Morpholino

MO1-ptpn6

ID
ZDB-MRPHLNO-140506-1
Name
MO1-ptpn6
Previous Names
None
Target
Sequence
5' - ACTCATTCCTTACCCGATGCGGAGC - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
Splice-blocking MO.
Genome Resources
None
Target Location
Genomic Features
No data available
Expression
Gene expression in Wild Types + MO1-ptpn6
Phenotype
Phenotype resulting from MO1-ptpn6
Phenotype of all Fish created by or utilizing MO1-ptpn6
Phenotype Fish Conditions Figures
heart edematous, abnormal AB/TL + MO1-ptpn6 standard conditions Fig. S1 from Marín-Juez et al., 2014
inflammatory response increased process quality, abnormal WT + MO1-ptpn6 standard conditions Fig. 3 from Kanwal et al., 2013
whole organism decreased life span, abnormal WT + MO1-ptpn6 bacterial treatment Fig. 5 from Kanwal et al., 2013
eye decreased size, abnormal WT + MO1-ptpn6 standard conditions Fig. 1 from Kanwal et al., 2013
integument damaged, abnormal WT + MO1-ptpn6 standard conditions Fig. 1 from Kanwal et al., 2013
retina mitotic cell cycle increased process quality, abnormal WT + MO1-ptpn6 standard conditions Fig. 3 from Kanwal et al., 2013
apoptotic process increased process quality, abnormal WT + MO1-ptpn6 standard conditions Fig. 3 from Kanwal et al., 2013
eye damaged, abnormal WT + MO1-ptpn6 standard conditions Fig. 1 from Kanwal et al., 2013
brain mitotic cell cycle increased process quality, abnormal WT + MO1-ptpn6 standard conditions Fig. 3 from Kanwal et al., 2013
heart edematous, abnormal WT + MO1-ptpn6 standard conditions Fig. 1 from Kanwal et al., 2013
leukocyte accumulation heart anatomical region, abnormal WT + MO1-ptpn6 standard conditions Fig. 3 from Kanwal et al., 2013
blood island lacks all parts of type leukocyte, abnormal WT + MO1-ptpn6 standard conditions Fig. 3 from Kanwal et al., 2013
head decreased size, abnormal WT + MO1-ptpn6 standard conditions Fig. 1 from Kanwal et al., 2013
innate immune response decreased process quality, abnormal WT + MO1-ptpn6 bacterial treatment Fig. 5 from Kanwal et al., 2013
yolk syncytial layer edematous, abnormal WT + MO1-ptpn6 standard conditions Fig. 1 from Kanwal et al., 2013
extension edematous, abnormal WT + MO1-ptpn6 standard conditions Fig. 1 from Kanwal et al., 2013
innate immune response process quality, abnormal WT + MO1-ptpn6 bacterial treatment Fig. 5 from Kanwal et al., 2013
leukocyte accumulation heart anatomical region, abnormal i114Tg + MO1-ptpn6 chemical treatment: pharmaceutical Fig. 4 from Kanwal et al., 2013
inflammatory response increased process quality, abnormal i114Tg + MO1-ptpn6 chemical treatment: pharmaceutical Fig. 4 from Kanwal et al., 2013
leukocyte accumulation heart anatomical region, abnormal i114Tg + MO1-ptpn6 standard conditions Fig. 4 from Kanwal et al., 2013
Citations